Pharma companies are spending billions on AI and automation, yet most projects remain trapped in "pilot purgatory". Why is digital transformation so difficult to scale on the manufacturing floor?

In this episode of Game of Pharma, host Lokesh Sharma sits down with Jonathon Thompson, Global Director of the Digital Center of Excellence at CAI. Drawing from a 25-year career arc,starting as a bench chemist on Eli Lilly's insulin line in 1999 to leading global automation strategies at Baxter, Avivia, and CAI—Jonathon reveals what it actually takes to move beyond AI hype into scalable operational value.

Key Topics Covered:

• From Bench Chemist to IT Leader: The LIMS & EBR Transition

• Why Pharma Under-Invests in Manufacturing AI vs. R&D

• Root Causes of "Pilot Purgatory" & How to Break Free

• Boardroom Expectations vs. Plant-Floor Operational Reality

• Big Pharma Tech Debt vs. Agile Biotech Startups

• The Hidden AI Opportunity in Tech Transfer & Scale-Up

• Micro-AI Solutions vs. Big-Bang Software Implementations

• Build, Buy, or Partner? Navigating AI Vendor Selection

• AI Founder vs. Pharma Founder Startup Models

Connect with Guest & Host:

Jonathon Thompson (CAI)

/ jonathon-thompson-1052906

Lokesh Sharma (Game of Pharma)

/ lokesh-sharma-7250a71a9

10,000 amputations happen every single day in India due to chronic wounds like diabetic foot ulcers, a silent epidemic hiding in plain sight.

In this episode of Game of Pharma, host Lokesh Sharma sits down with Tarun Bansal, Co-founder of MedVital and former key leader at Pristyn Care and EY, to unpack how advanced medical devices can solve India's massive healthcare white spaces.

While India has proven its dominance in global pharma, the medical device sector remains drastically underpenetrated. Tarun breaks down how MedVital is disrupting wound care through accessible Negative Pressure Wound Therapy (NPWT), chitosan-based liquid bandages made from seafood waste, and sheep tissue-derived extracellular matrices to drive complete skin restoration.

Discover why medical devices are poised to follow pharma's high-growth trajectory, the realities of scaling a B2B MedTech startup, and how to change doctor adoption behavior on the ground.

Subscribe to Game of Pharma for more deep-dive conversations with global healthcare and pharmaceutical leaders!

Subscribe for Elite Business & Pharma Insights: / @gameofpharma-podcast

Connect with Tarun Bansal on LinkedIn: / tarun-bansal-6a61b3a

LISTEN ON PODCAST:

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4EDgDoe...

Website: https://gameofpharma.com/

GAME OF PHARMA NEWSLETTER:

Weekly pharma insights delivered to your inbox

Subscribe: https://game-of-pharma.beehiiv.com

CONNECT WITH HOST - LOKESH SHARMA

LinkedIn: / lokesh-sharma-7250a71a9

FOLLOW GAME OF PHARMA:

LinkedIn: / game-of-pharma-podcast

Instagram: / gameofpharma

Why are commercial insurance systems structurally built to reject permanent medical cures? In this episode of Game of Pharma, host Lokesh Sharma sits down with Dr. Elizabeth Aden, Ex-SVP of Global Pharma Strategy at Roche and Advisor at SPARK at Stanford to unpack the hidden economic machinery behind drug development, portfolio allocation, and commercial launch strategy.

From the financial trap of chasing 3% of a mega-market to why US payers prefer funding annual chronic maintenance over one-time $80,000 cures, this conversation exposes the boardroom calculus that dictates global healthcare.

WHAT WE COVER IN THIS EPISODE:

• Commercial Profits vs. Community Cures: Why fragmented payer models penalize curative single-dose therapies.

• The 80/3 Portfolio Equation: Why owning 80% of a targeted niche yields superior bottom-line returns over chasing a volatile 3% of a broad disease market.

• The Drug Repurposing Opportunity: Why companies spend billions developing new molecules from scratch while golden assets gather dust in corporate archives.

• Promotional Overhead & Marketing Friction: How sales and marketing expenses quietly devour blockbuster drug profitability.

• Stanford SPARK Insights: Translating academic discoveries into commercially viable startups.

CONNECT WITH DR. ELIZABETH ADEN

LinkedIn: / elizabeth-reed-aden

EXPLORE THE FICTION SIDE OF PHARMA STRATEGY:

Interested in how personalized medicine, genetic profiling, and prescription dosing collide in a high-stakes medical thriller? Check out Dr. Elizabeth Aden’s bestseller The Goldilocks Genome.

Get it on Amazon: https://www.amazon.in/Goldilocks-Geno...

CONNECT WITH HOST - LOKESH SHARMA

LinkedIn: / lokesh-sharma-7250a71a9

FOLLOW GAME OF PHARMA:

LinkedIn: / game-of-pharma-podcast

Instagram: / gameofpharma

ABOUT OUR GUEST:

Dr. Elizabeth Aden is a veteran pharmaceutical executive, board member, and author. She previously served as Senior Vice President & International Director of Global Pharma Strategy at Roche, where she managed global portfolio research across six international sites. She is currently an Advisor at SPARK at Stanford, a board member at JVS Medical, and has led multiple biotech companies dedicated to recovering shelved pharmaceutical assets.

ABOUT GAME OF PHARMA:

Game of Pharma is one of the bes podcast for life science professionals, corporate strategists, student researchers, and biotech entrepreneurs exploring the intersection of medicine, market access, and commercial strategy.

Is "work-life balance" in your 20s a lie? Should you job-hop every 2 years to grow, or is corporate loyalty still worth it?

In this deep-dive episode of Game of Pharma, host Lokesh Sharma sits down with Anand Agarwal (Senior Vice President & Regional Head at Cipla). From his humble beginnings in a small town in Rajasthan (Abu Road) to completing 25 years at Cipla and leading international markets, Anand shares unfiltered career truths for young professionals, freshers, medical reps, and corporate leaders.

Key Highlights in This Episode:

• The "Balanced Life" Framework: Why separating "work" from "life" is flawed, and why 100% presence beats work-life balance.

• Advice for Fresh Medical Reps (MRs): How to navigate the initial field grind, upskill, and avoid burnout.

• The 20s Money Trap: Why chasing overhyped wealth and comparing yourself to internet founders can ruin your personal life.

• 25 Years at ONE Company: Why Anand stayed at Cipla for a quarter-century and what makes a company worth staying at.

• The 3 Non-Negotiable Pillars: Growth, Earnings, and Respect—the real metric for deciding whether to stay or switch jobs.

• What Gen Z Wants: Why respect in the workplace is the ultimate retention factor for the next generation.

Subscribe to Game of Pharma for more deep-dive conversations with global healthcare and pharmaceutical leaders!

Subscribe for Elite Business & Pharma Insights: / @gameofpharma-podcast

Connect with Anand Agarwal on LinkedIn: / anandagarwal-leadership

LISTEN ON PODCAST:

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4EDgDoe...

Website: https://gameofpharma.com/

GAME OF PHARMA NEWSLETTER:

Weekly pharma insights delivered to your inbox

Subscribe: https://game-of-pharma.beehiiv.com

CONNECT WITH HOST - LOKESH SHARMA

LinkedIn: / lokesh-sharma-7250a71a9

FOLLOW GAME OF PHARMA:

LinkedIn: / game-of-pharma-podcast

Instagram: / gameofpharma

What does it take to scale a career across the global pharmaceutical industry over 38 years? In this podcast, N. Chandrasekaran, Associate Vice President at NATCO Pharma (Ex-Sandoz, Ex-Novartis, Ex-Biocon), breaks down the unwritten rules of corporate pharma growth, commercial sales team execution, and executive leadership.

If you are a Medical Representative (MR), Area Business Manager (ABM), or pharmaceutical professional looking to grow into executive positions, this episode provides a practical blueprint.

Chandrasekaran shares a contrarian take on corporate culture, declaring organization culture a myth and explaining why leadership rests entirely with line managers. He details how to manage remote field teams over Zoom, leverage the 5W blueprint to convert raw effort into sales goals, and apply the golden rule of executive communication: praise in public, critique in private.

Looking for a proven pharma sales strategy, a clear career growth plan, or actionable team management advice from top life sciences executives? This detailed discussion covers pharmaceutical commercial operations, MNC vs Indian pharma corporate frameworks, and field force execution metrics.

Learn how to navigate the shift from entry-level medical representative roles to high-level regional manager positions, track field force effort logs without micro-managing, pitch high-priced innovator molecules, and use the 5W framework to align remote field teams over online meetings.

Connect with N. Chandrasekaran on LinkedIn: / n-chandrasekaran-23b73572

LISTEN ON PODCAST:

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4EDgDoe...

Website: https://gameofpharma.com/

GAME OF PHARMA NEWSLETTER:

Weekly pharma insights delivered to your inbox

Subscribe: https://game-of-pharma.beehiiv.com

CONNECT WITH HOST - LOKESH SHARMA

LinkedIn: / lokesh-sharma-7250a71a9

FOLLOW GAME OF PHARMA:

LinkedIn: / game-of-pharma-podcast

Instagram: / gameofpharma

How do you survive and dominate an Indian pharma market where 60,000 generic brands launch every single year? Dr. Vijay Charlu (President - India Business, Corona Remedies Limited) breaks down the ultimate playbook for molecule selection, market disruption, and successful brand acquisitions.

The rules of the pharmaceutical industry have fundamentally shifted. Traditional marketing is dead, and market disruption is the new norm. In this episode of Game of Pharma, we sit down with Dr. Vijay Charlu to uncover why scaling matters more than product value, how to spot portfolio gaps, and the real reason most private equity pharma acquisitions fail (Hint: It’s not the money).

If you are a pharma executive, marketer, entrepreneur, or investor looking to understand the mechanics of the Indian drug market, this masterclass is for you.

If you found this breakdown valuable, don't forget to Like, Subscribe, and hit the Notification Bell to stay ahead of the curve in the pharma ecosystem!

Connect with Dr. Vijay Charlu on LinkedIn: / vijaycharlu

LISTEN ON PODCAST:

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4EDgDoe...

GAME OF PHARMA NEWSLETTER:

Weekly pharma insights delivered to your inbox

Subscribe: https://game-of-pharma.beehiiv.com

Host LinkedIn - / lokesh-sharma-7250a71a9

Follow us on social media -

Website : https://gameofpharma.com/

Instagram : https://www.instagram.com/gameofpharm...

LinkedIn : / game-of-pharma-podcast

How did a local Indian health platform secure millions from Japanese giant Mitsubishi, sell a majority stake to Flipkart, and then pull off a historic buyback when global strategies shifted?

In this episode of Game of Pharma by Game Of Pharma, host Lokesh sits down with Mr. B.L. Mittal, the legendary founder of SastaSundar. Mr. Mittal cracks open the reality of the Indian healthcare ecosystem, pulling back the curtain on how a business built on "Tech + Empathy" disrupted the complex digital retail pharmacy space.

From growing up in rural Rajasthan and unlocking the foundational philosophies of the "Marwari Business Code" to navigating multi-million dollar equity deals, Mr. Mittal's journey is a clinic in masterclass unit economics. He outlines the dangerous landscape where 50% of rural Indian prescriptions are dictated by unqualified practitioners, the tragic personal events that fueled his healthcare vision, and why traditional retail models consistently outperform over-leveraged tech startups. If you want to understand structural risk management, sustainable corporate scaling, and why PharmEasy’s aggressive expansion patterns structuralized a deep decline, this conversation is an absolute necessity.

Key Topics Explored:

The calculated mechanics behind the historic 10-minute Flipkart-SastaSundar buyback deal.

Brand Architecture: Why simple experience-driven taglines disrupt markets faster than premium naming agencies.

The Hub and Spoke logistics model that maintains structural profitability without zero-margin inventory.

Why Indian pharma spaces under-invest in core R&D compared to global operations like Eli Lilly.

Pragmatic advice for early-stage entrepreneurs looking to preserve equity and drive cash-flow longevity.

Subscribe to Game Of Pharma for weekly masterclasses with global healthcare pioneers.

Formulate your strategies directly via our network profiles.

Subscribe for Elite Business & Pharma Insights: / @gameofpharma-podcast

Connect with on LinkedIn: / blmittal

LISTEN ON PODCAST:

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4EDgDoe...

Website: https://gameofpharma.com/

GAME OF PHARMA NEWSLETTER:

Weekly pharma insights delivered to your inbox

Subscribe: https://game-of-pharma.beehiiv.com

CONNECT WITH HOST - LOKESH SHARMA

LinkedIn: / lokesh-sharma-7250a71a9

FOLLOW GAME OF PHARMA:

LinkedIn: / game-of-pharma-podcast

Instagram: / gameofpharma